Pricing Log in Create free account

Alumis Inc. (ALMS) vs Lexicon Pharmaceuticals, Inc. (LXRX)

Alumis Inc. and Lexicon Pharmaceuticals, Inc. are both Biotechnology companies. Alumis Inc. and Lexicon Pharmaceuticals, Inc. are of similar size ($780.9M and $716.4M). Lexicon Pharmaceuticals, Inc. has the higher net margin (−161.8% vs −5,933.5%) and the lower return on invested capital (−109.1% vs 0.00%). Across the 16 metrics below, Lexicon Pharmaceuticals, Inc. leads on 11 and Alumis Inc. on 5.

Valuation

Metric ALMS LXRX Biotechnology median
P/E n/m n/m 10.60
P/S 103.91 20.67 9.40
P/B 1.70 4.86 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 36.01 17.38 9.02
Earnings yield (63.00%) (8.05%) (32.88%)
Free cash flow yield (45.77%) (6.31%) (23.13%)

Profitability

Metric ALMS LXRX Biotechnology median
Gross margin 100.00% 98.89% 68.51%
Operating margin (6,204.39%) (147.42%) 0.00%
Net margin (5,933.45%) (161.80%) 0.00%
Free cash flow margin (4,755.33%) (127.76%) 0.00%
Return on equity (93.65%) (43.91%) (51.96%)
Return on assets (74.94%) (27.84%) (46.06%)
Return on invested capital 0.00% (109.13%) 0.00%

Growth

Metric ALMS LXRX Biotechnology median
Revenue growth (TTM) — (45.62%) 6.76%
EPS growth (last fiscal year) 72.45% 77.78% 29.88%
Revenue growth, 5-year CAGR — 15.72% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ALMS LXRX Biotechnology median
Debt to equity 0.00 0.32 0.00
Current ratio 6.74 10.63 4.97
Net debt to EBITDA 0.69 0.91 1.01

Dividend

Metric ALMS LXRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALMS LXRX Biotechnology median
Market cap 780.94m 716.37m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack